Does The Data Supplment Bristol-Myers Squibb Company (NYSE:BMY) Movement?

12

Bristol-Myers Squibb Company (NYSE:BMY) closed its last session at $65.35. The stock traded within a range of $63.27 and $65.94. The company operates in the Healthcare sector with a market capitalization of 106.94 Million. Trading volume for Bristol-Myers Squibb Company was 10.29 Million in its previous trading session. Currently, Bristol-Myers Squibb Company (NYSE:BMY) has an average volume of 6.72 Million.

Company Profile

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients – it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.

Analyst Views

Bristol-Myers Squibb Company (NYSE:BMY) received a Buy rating from 2 analysts. 0 analysts gave its stock an Outperform rating. 3 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.

Bristol-Myers Squibb Company (NYSE:BMY) touched its 1-Year High price of $66.10 on 10/13/17 and its 1-Year Low price of $51.56 on 06/07/17.

EPS & Financials

Bristol-Myers Squibb Company (NYSE:BMY) reported its EPS in the last quarter as $0.68/Share beating the analyst estimate of $0.67/Share by a difference of $0.01. This showed a surprise of 1.5% in the last quarter earnings.

For the current quarter, 15 analysts are projecting a mean EPS of $0.84/share. According to their observations and findings, the stock could provide a high EPS of $0.98/share and a low EPS of $0.74/share.

Analysts believe that the company has the potential to earn average revenue of $5.19 Billion for the current quarter. According to their predictions high & low revenue estimates are 5.33 Billion and 5 Billion respectively.

Technical Analysis

By taking a look at the stock’s current statistics it can gauged that the stock candle is BULLISH with HIGH volatility. Bristol-Myers Squibb Company (NYSE:BMY) has a 20-Day average volume of 9.66 Million. According to today’s trading volume Bristol-Myers Squibb Company is ABOVE its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.

Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BULLISH territory while an analysis of the last 40-Day trend shows a BULLISH signal. The 100-Day trend also shows a BEARISH trend as well.

The company currently has an insider ownership of 0.1 Percent and Institutional ownership of 71.3 Percent. The return on assets stands at 13.7%, Return on Equity currently is 30.5% and the Return on Investment value is 19.8%.

Bristol-Myers Squibb Company (NYSE:BMY) gross margin percentage stands at 71.5% while its operating margin for the past trailing twelve month is 28.8 percent and its overall profit margin (ttm) is 22.1 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 3.86% with a 50-Day Simple Moving Average of 4.84 percent. As of today, the company has a SMA200 (200-day simple moving average) of 9.8 Percent. The Stock has YTD (year to date) performance of 6.64 percent.

The TTM operating margin for the company stands at 28.8%. The return on invested capital is at 19.8%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 64.89.

The company’s stock is currently moving with a +ve distance from the 200 day SMA of approximately 9.8%, and has a solid year to date (YTD) performance of 6.64% which means that the stock is constantly adding to its value from the previous fiscal year end price.